Log In
Print this Print this

IFN-beta-CTP (intravenous) (MOD-9023)

  Manage Alerts
Collapse Summary General Information
Company Opko Health Inc.
DescriptionIV long-acting formulation of interferon (IFN) beta-1a developed using Prolor's CTP technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today